AOD-9604 vs HGH Fragment 176-191: same molecule, different story

If you've shopped peptides for fat loss, you've seen both names: AOD-9604 and HGH Fragment 176-191. The vendor copy often treats them as variations of the same product. The pricing is roughly similar. Some peptide retailers list them on the same page. So if they're the same fragment of growth hormone, what's actually different?

The short answer: the molecule is essentially the same. The story is not. The difference matters when you're trying to understand which dose schedule has any human evidence behind it, which one has been through a regulatory pathway, and whether the bottle you're looking at represents a research compound or a once-clinically-developed drug.

The molecule

Growth hormone is a 191-amino-acid protein. In the late 1980s, researchers at Monash University in Australia hypothesized that the fat-mobilizing activity of GH was concentrated in a specific region of the molecule — the C-terminal end. They isolated and synthesized the C-terminal fragment running from amino acid 176 to 191 and demonstrated that it preserved the lipolytic (fat-releasing) and anti-lipogenic activity of intact GH while removing most of the growth-promoting effects on bone, organs, and IGF-1 production.

This 16-amino-acid sequence is hGH Fragment 176-191.

AOD-9604 is that same sequence with a single modification: a tyrosine residue added to the N-terminus (sometimes written as Tyr-hGH 177–191 in the early literature). The added tyrosine was used during development for radiolabeling and biological assay work and was retained in the final clinical candidate.

For practical purposes, AOD-9604 ≈ HGH Fragment 176-191 + an extra tyrosine. The molecular weight is essentially the same. The mechanism is the same. The receptor target — to the extent one has been identified — is the same.

So why two products with two names?

The divergent histories

Here's where the molecule becomes two stories.

HGH Fragment 176-191 is the academic / research-chemical version. It came out of the Monash work in the 1980s and 1990s, was characterized as a fat-loss fragment in preclinical models, and was synthesized by various research-supply houses for laboratory use. It never went through a serious clinical-trial program as 176-191.

AOD-9604 went through clinical development. Metabolic Pharmaceuticals (a spinout of the Monash research group) developed AOD-9604 as a candidate obesity drug through the late 1990s and 2000s. The clinical program is the entire reason there's any human data on this fragment at all.

The AOD-9604 clinical story:

• Phase 2a trials (early 2000s) suggested modest fat loss effects in obese subjects with reasonable tolerability
• A larger Phase 2b trial (Heffernan et al., 2001 work and follow-on studies) failed to demonstrate clinically meaningful weight loss versus placebo at the doses tested. The compound did not meet endpoints sufficient to justify a Phase 3 program for obesity.
• The program was effectively shelved for obesity in the mid-2000s
• AOD-9604 was repositioned and trialed as a potential osteoarthritis treatment — particularly for cartilage protection — with some signals but no commercial approval
• It received GRAS (Generally Recognized As Safe) status from the FDA in 2014 as a food/supplement ingredient, which is regulatory-different from drug approval but matters for understanding what AOD-9604 is allowed to be in the US

The HGH Fragment 176-191 story is much shorter: synthesized as a research compound, used in some animal work, and sold to the research-chemical and biohacker markets without a parallel clinical program of its own.

What this means for the fat-loss claim

The headline question for most readers: does either of these actually work for fat loss in humans?

The most honest read of the AOD-9604 clinical data is "modest effect at best, not clinically significant in the obesity trials." The compound didn't fail because it had no biological activity — there are signals in the data — but because the magnitude of effect at tolerated doses wasn't enough to justify continued development against the bar set by other obesity drugs.

For lean or near-lean strength-peptide users (the typical audience here, not the morbidly obese population in those trials), the question is different and unanswered. The clinical program wasn't designed to detect modest body-composition shifts in already-lean athletes. We don't have data either way for that population.

What we can say:

• The fragment is well-tolerated in the doses studied
• It does not raise IGF-1 meaningfully, unlike GH or GH secretagogues — which is the whole design intent
• It does not produce the joint and metabolic side effects associated with GH
• The fat-loss effect, if real in athletes, is small and not separable from caloric deficit and training

For the broader frame on fat-loss peptides, see HGH fragment 176-191 fat loss guide and cutting with peptides: what works.

Practical differences when buying

When you're looking at vendor pages, here's what actually differs:

The "buy AOD-9604 instead" argument is really an argument that you trust the GRAS status and clinical program as a signal of identity/quality more than you trust a generic research-chemical 176-191. Whether that signal is meaningful depends on how rigorous the vendor's sourcing is — GRAS status applied to a specific synthesis is different from "your vendor's batch happens to be GRAS-eligible."

Where the confusion comes from

A few things compound the confusion:

Vendors sometimes label HGH Fragment 176-191 as "AOD-9604" without the tyrosine modification. This is mislabeling. The two are not the same product, even though the pharmacological behavior is expected to be very similar. A COA showing 176-191 sequence without the N-terminal tyrosine is not AOD-9604.

Some literature uses "AOD-9401" to refer to an earlier candidate in the same program. AOD-9401 is a different N-terminal modification (a methionine instead of tyrosine, in early formulations). It's mostly of historical interest.

Community discussions conflate dose schedules. Recommendations like "AOD at 300 mcg fasted" and "176-191 at 500 mcg fasted" floating around forums are not based on differential pharmacology — they're community consensus that drifted into separate numbers despite the molecule being essentially the same.

For reading a COA carefully enough to catch sequence-level differences, see reading a COA: worked example.

Who should care about the distinction

For most practical buying purposes, the distinction doesn't change your protocol. The dose, timing, and expectations are similar.

It matters more if you're:

• Trying to source the version with a clinical-trial history (in which case insist on AOD-9604 specifically, with COA sequence verification showing the N-terminal tyrosine)
• In a regulatory context where GRAS status of one but not the other matters
• Comparing studies in the literature — make sure you're reading about the version your vendor is selling, not the other one
• Stacking carefully — if you're combining with GH secretagogues, knowing what exactly you're injecting matters more than usual

If none of those describe you, you can largely treat them as interchangeable in protocol design while preferring the better-documented vendor.

The honest framing

AOD-9604 has the regulatory paper trail. HGH Fragment 176-191 is the underlying molecule without it. Both have weak human evidence for fat loss in the populations actually studied, and effectively no evidence in the lean strength-athlete population. The marketing of either as a meaningful fat-loss tool gets ahead of the data.

If you're picking one for a stack — say with Ipamorelin and CJC-1295 during a cut — the choice between them is more about vendor credibility than pharmacology. Pick the version you can verify, dose conservatively, and don't expect transformative effects on top of what diet and training already produce.

Related reading

• HGH fragment 176-191 fat loss guide
• AOD-9604 clinical history and peptide market
• Cutting with peptides: what works
• Tesamorelin and visceral fat literature
• Vendor due diligence checklist